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INTRODUCTION
The STandards for Reporting Interventions 
in Clinical Trials of Acupuncture (STRICTA) 
reporting guidelines, ﬁ   rst published in 
2001,1–9 were designed to improve the 
completeness and transparency of report-
ing of interventions in controlled trials of 
acupuncture, in order that such trials may 
be more accurately interpreted and readily 
replicated. STRICTA comprised a checklist 
that expanded the generic content of item 
4 of the CONSORT statement,10 11 which 
relates to the reporting of the intervention.
A survey of authors of clinical trials 
and systematic reviews was subsequently 
conducted to determine the usefulness 
The combination of these develop-
ments led to an agreement between the 
CONSORT Group and the STRICTA 
Group, in collaboration with the Chinese 
Cochrane Centre and the Chinese 
Centre for Evidence-based Medicine, to 
revise STRICTA as a formal extension 
to CONSORT. The revision processes 
have been described in more detail 
elsewhere.17 This paper describes the 
  outcome and new checklist, updated 
explanations and published examples of 
good reporting.
METHODS
In the summer of 2008, a group of 47 
experts from the original STRICTA 
Group, the CONSORT Group, the 
World Federation of Acupuncture and 
Moxibustion Societies, the Acupuncture 
Trialists’ Collaboration,18 the Society for 
Acupuncture Research19 and clinical trial 
authors were surveyed.12 The experts 
were from 15 countries, 41 had academic 
positions, 31 were acupuncturists, 18 were 
involved with journals, such as board 
members, 15 were doctors and 11 had 
previously helped in developing reporting 
guidelines. These experts were consulted 
about a draft of revised STRICTA items 
that had evolved from previous research.12 
13 Feedback was collated and forwarded 
(with permission) to those invited to a 
consensus development workshop, the 
next phase of the revision process.
Twenty-one people attended a work-
shop in Freiburg, Germany, in October 
2008. The attendees included experts in 
epidemiology, trial methodology, statis-
tics and medical journal editing. Just over 
half the participants were acupuncturists 
from a variety of backgrounds, includ-
ing doctors and non-doctors. All attend-
ees received collated feedback from the 
47 experts, together with a draft revised 
STRICTA checklist for consideration.
The workshop comprised presenta-
tions about the history of STRICTA, 
CONSORT and the then new CONSORT 
non-pharmacological treatments exten-
sion.14 15 The results of two investiga-
tions into the utility and acceptability 
of STRICTA,12 13 and the subsequent 
consultation with the 47 experts, were 
also presented. A general discussion and 
agreement on generic issues relating to 
STRICTA were followed by a discussion 
of each nominated checklist item. The 
aim was to agree, where possible, on the 
content of the updated draft checklist as 
well as to develop a revised set of expla-
nations for each included item.
Revised STandards for Reporting 
Interventions in Clinical Trials of 
Acupuncture (STRICTA): extending the 
CONSORT statement
ABSTRACT
The STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) were published 
in ﬁ  ve journals in 2001 and 2002. These guidelines, in the form of a checklist and explanations for 
use by authors and journal editors, were designed to improve reporting of acupuncture trials, particu-
larly the interventions, thereby facilitating their interpretation and replication. Subsequent reviews 
of the application and impact of STRICTA have highlighted the value of STRICTA as well as scope for 
improvements and revision.
To manage the revision process a collaboration between the STRICTA Group, the CONSORT Group 
and the Chinese Cochrane Centre was developed in 2008. An expert panel with 47 participants was 
convened that provided electronic feedback on a revised draft of the checklist. At a subsequent 
face-to-face meeting in Freiburg, a group of 21 participants further revised the STRICTA checklist 
and planned dissemination.
The new STRICTA checklist, which is an ofﬁ  cial extension of CONSORT, includes 6 items and 17 
subitems. These set out reporting guidelines for the acupuncture rationale, the details of needling, 
the treatment regimen, other components of treatment, the practitioner background and the con-
trol or comparator interventions. In addition, and as part of this revision process, the explanations 
for each item have been elaborated, and examples of good reporting for each item are provided. 
In addition, the word ‘controlled’ in STRICTA is replaced by ‘clinical’, to indicate that STRICTA is 
applicable to a broad range of clinical evaluation designs, including uncontrolled outcome studies 
and case reports. It is intended that the revised STRICTA checklist, in conjunction with both the 
main CONSORT statement and extension for non-pharmacological treatment, will raise the quality of 
reporting of clinical trials of acupuncture.
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http://
aim.bmj.com/info/unlocked.dtl
Hugh MacPherson,1 Douglas G Altman,2 Richard 
Hammerschlag,3 Youping Li,4 Taixiang Wu,4 Adrian White,5 
David Moher6; on behalf of the STRICTA Revision Group
of STRICTA in helping them to write 
their reports.12 In addition, a survey of 
90 acupuncture trials was undertaken 
to assess whether use of the STRICTA 
checklist was associated with improved 
reporting over time.13 The results of these 
initiatives led to conclusions that most 
STRICTA items were found to be neces-
sary and easy to use, though some were 
seen as poorly reported, ambiguous or 
possibly redundant and a number of sug-
gestions were made for additional items. 
A revision of STRICTA was therefore 
proposed.
Meanwhile, extensions to CONSORT 
have been developed to cover the report-
ing of non-pharmacological treatments14 
15 and pragmatic trials.16 Since there are 
acupuncture-speciﬁ  c aspects to reporting 
not covered by these extensions, it was 
decided that STRICTA should be revised 
in a manner congruent with CONSORT 
and its extensions for non-pharmacologi-
cal treatments and pragmatic trials.
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Subsequent to the workshop, a small 
writing group edited drafts of the revised 
STRICTA checklist, identifying for each 
item one or more exemplars of good 
reporting, and developed text explaining 
the rationale and discussing relevant evi-
dence. Taking into account further feed-
back from those attending the Freiburg 
workshop, the writing group ﬁ  nalised the 
STRICTA checklist, the explanations and 
the examples of good reporting.
RESULTS
There was agreement that STRICTA 
should continue to function as a stand-
alone guideline for reporting acupunc-
ture studies and be an ofﬁ  cial extension 
of CONSORT for reporting randomised 
controlled trials. There was also consen-
sus on a minor change of name, in that 
the word ‘controlled’ in STRICTA should 
be replaced by ‘clinical’, to indicate that it 
was applicable for reporting a broad range 
of clinical evaluation designs, including 
uncontrolled outcome studies and case 
reports. The group agreed that the ratio-
nale behind reporting should be to pro-
vide the information needed to allow 
replication of a study, reduce ambiguity 
and enhance transparency. The group rec-
ognised that acupuncture trials inevitably 
differ in the degree of individualisation of 
care that is permitted and agreed that the 
reporting guideline should acknowledge 
this and be applicable across the whole 
range of designs. The group also suggested 
that the revised STRICTA statement, 
when published, should be presented as 
embedded within the two-group parallel 
trial CONSORT checklist10 and its non-
pharmacological treatment extension 
checklist.14
The revised STRICTA checklist com-
prises six items split into 17 subitems (table 
1). Table 2 presents details of the way in 
which the revised STRICTA checklist ﬁ  ts 
within the CONSORT checklist10 and its 
extension for non-pharmacological treat-
ments.14 Below we provide the checklist text 
for each of the six items and their subitems, 
as well as explanations on the need for their 
adequate reporting and examples of good 
reporting from the published literature.
STRICTA ITEM 1: ACUPUNCTURE 
RATIONALE
Item 1a: Style of acupuncture (eg, 
Traditional Chinese Medicine (TCM), 
Japanese, Korean, Western medical, Five 
Element, ear acupuncture, etc)
Explanation
Acupuncture has a long history in many 
cultures and is characterised by a broad 
diversity of styles and approaches in both 
East Asia and the West.20 In order for 
readers to contextualise the trial within 
the range of current clinical practices, 
researchers should state the overall style 
or approach on which they have based 
the treatments. If the researcher believes 
the treatment approach is completely 
novel, then this should be clearly stated.
Examplesi
(A)  We based the acupuncture point selec-
tions on traditional Chinese medi-
cine (TCM) meridian theory to treat 
knee joint pain, known as the ‘Bi’ 
syndrome.21
(B)  Participants were randomised to two 
styles of acupuncture: Japanese style 
(Kiiko-Matsumoto’s Form) and TCM 
style.22
(C) Four out of ﬁ  ve of the acupuncturists 
primarily practised the Five Element 
style with a diagnostic focus on indi-
vidual ‘causative factors’, (ref) and 
one used the Traditional Chinese 
Medicine style with diagnosis primar-
ily based on syndrome patterns. (ref) 
Both styles are rooted in traditional 
acupuncture theory, and they are the 
most common traditional approaches 
used by professional acupuncturists 
in the UK today (ref).23
(D) Each patient was treated with non-
  local needle acupuncture (according to 
the theory of channels of TCM) at dis-
tant points and dry needling of local 
myofascial trigger points (TRPs).24
Item 1b: Reasoning for treatment 
provided, based on historical context, 
literature sources and/or consensus 
methods, with references where 
appropriate
Explanation
The author(s) should provide the reason-
ing for the chosen treatment, including 
rationale for diagnosis, point selection 
and treatment procedures. The ‘rules’ that 
were used in providing treatments should 
be described. When treatments were 
selected that have roots in traditional prac-
tice, it is recommended that the historical 
and cultural context be supplied. This is 
relevant for interventions within styles 
such as Traditional Chinese Medicine, 
where the broad diversity of approaches 
Table 1  Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) 
items that replace CONSORT 2010 item 5 when reporting an acupuncture trial
(1) Acupuncture rationale (1a) Style of acupuncture (eg, Traditional Chinese Medicine, Japanese, Korean, 
Western medical, Five Element, ear acupuncture, etc)
(1b) Reasoning for treatment provided, based on historical context, literature sources 
and/or consensus methods, with references where appropriate
(1c) Extent to which treatment was varied
(2) Details of needling (2a) Number of needle insertions per subject per session (mean and range where 
relevant)
(2b) Names (or location if no standard name) of points used (uni-/bilateral)
(2c) Depth of insertion, based on a speciﬁ  ed unit of measurement or on a particular 
tissue level
(2d) Responses sought (eg, de qi or muscle twitch response)
(2e) Needle stimulation (eg, manual or electrical)
(2f) Needle retention time
(2g) Needle type (diameter, length and manufacturer or material)
(3) Treatment regimen (3a) Number of treatment sessions
(3b) Frequency and duration of treatment sessions
(4) Other components of 
treatment
(4a) Details of other interventions administered to the acupuncture group (eg, moxi-
bustion, cupping, herbs, exercises, lifestyle advice)
(4b) Setting and context of treatment, including instructions to practitioners, and 
information and explanations to patients
(5) Practitioner background (5) Description of participating acupuncturists (qualiﬁ  cation or professional afﬁ  liation, 
years in acupuncture practice, other relevant experience)
(6) Control or comparator 
interventions
(6a) Rationale for the control or comparator in the context of the research question, 
with sources that justify the choice(s)
(6b) Precise description of the control or comparator. If sham acupuncture or any 
other type of acupuncture-like control is used, provide details as for items 1–3 above
This checklist should be read in conjunction with the explanations of the Standards for Reporting Interventions in 
Clinical Trials of Acupuncture items provided in the main text.
iIn the Examples that follow, the embedded ref-
erences to ﬁ  gures, tables  and sources that are 
presented are where the authors have reported 
them in the published studies, and therefore 
details of these data are not provided in this 
article.
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requires   careful   identiﬁ   cation of where 
and when the treatment parameters were 
developed. Where consensus methods, 
expert clinical panels, practitioner surveys 
or some combination of sources have 
been used to deﬁ  ne the treatment proto-
col, it is recommended that full details of 
the methodology be given. Literature and 
other sources should be provided where 
relevant, in order that others can repli-
cate the trial by consulting these source(s) 
and/or developmental methods on which 
treatment was based. Authors are encour-
aged to reference published works that are 
easily obtainable, such as a book or jour-
nal article. If the   reference is a thesis, non-
published work, written material only 
available in a different language from the 
journal article, or a verbal communication, 
authors are encouraged to present or sum-
marise the information in an appendix or 
make it otherwise generally available (eg, 
on a website). For fully individualised tri-
als where the goal is to have representa-
tive practitioners who are encouraged to 
practise as they normally do, it is appro-
priate to specify the selection process for 
the practitioners, providing details of cri-
teria for their inclusion. It is important to 
note that where details of the intended 
intervention are deﬁ  ned in advance, it is 
possible that what was actually admin-
istered may have differed. In such cases, 
precise details of the treatments that were 
provided are also necessary.
Examples
(A)  This study employed a style of 
Japanese acupuncture developed by 
Shima and Chace (ref) and Manaka 
(ref), and follows the Japanese acu-
puncture training curriculum at the 
New England School of Acupuncture. 
In comparison with typical traditional 
Chinese medicine (TCM) acupuncture, 
Japanese acupuncture uses smaller 
needles and inserts needles less deeply 
and with less manipulation. (ref) For 
these reasons, we believed Japanese 
acupuncture would be less invasive 
than TCM and thus better received by 
our adolescent population. Japanese 
acupuncture has been shown to be 
effective in treating certain pain con-
ditions. (ref) The speciﬁ  c acupuncture 
protocols employed in this study are 
brieﬂ  y described below and discussed 
in greater detail in a companion paper 
(ref).25
(B) We based point selection on indi-
vidualised Western acupuncture 
techniques by using a list of points 
previously reported as being effective 
in neck pain (refs) and by reaching a 
consensus according to our own clin-
ical and teaching practice. (ref) The 
speciﬁ   c points for each individual 
were deﬁ  ned at each treatment ses-
sion, depending on the patient’s pain 
distribution and palpation of the neck 
and thorax to determine ah shi points 
or local tender points, for acupuncture. 
At least one distal point was used. 
Point location and depth of insertion 
were as described in traditional texts 
(ref).26
(C) We developed the treatment strate-
gies for acupuncture and minimal 
acupuncture in a consensus process 
with three acupuncture specialists 
(names provided) representing two 
major German societies for medical 
  acupuncture: the German Medical 
Acupuncture Association (Deutsche 
Ärztegesellschaft für Akupunktur) 
and the International Society for 
Chinese Medicine (Societas Medicinae 
Sinensis). The ﬁ  rst step involved three 
specialists (names provided) and the 
study team developing a proposal, 
which was followed by a discussion 
including more than 30 acupuncture 
experts from both acupuncture soci-
eties. The ﬁ  nal intervention strategies 
were deﬁ   ned by the above-men-
tioned three specialists together with 
the study team and subsequently 
were communicated to the external 
advisors.27
Item 1c: Extent to which treatment was 
varied
Explanation
The extent to which the treatment was 
individualised, both between patients 
and between practitioners, should be 
described. Trial protocols choose one of 
the three broad levels of individualisa-
tion, ranging from none at all (all patients 
receiving the same treatment at all ses-
sions), through partially individualised 
treatments (eg, use of a ﬁ  xed set of points 
to be combined with a set of points to 
be used ﬂ  exibly), to fully individualised 
treatment protocols within which each 
patient receives a unique and evolving 
diagnosis and treatment. Additionally, 
the practitioners may have to apply a 
standardised theoretical framework or 
may be allowed to apply their own. Many 
styles of acupuncture, whether based 
on traditional theories or Westernised 
concepts such as trigger points, are indi-
vidualised in routine practice. Trials that 
are more pragmatic28 in their aim, and 
designed to replicate routine settings and 
patient groups, place more of an empha-
sis on fully   individualised treatment. In 
such cases standardisation may consist 
of a protocol that instructs practitioners 
to provide treatments as they normally 
do. Trials that are more explanatory 
(mechanistic) in their aim tend to need a 
tighter deﬁ  nition of speciﬁ  c components 
in order to minimise variation across 
treatments.
Examples
(A) Each patient received individualised 
acupuncture treatments that focused 
on speciﬁ  c needs and symptoms that 
the individual was experiencing. The 
rationale for this intervention was 
to test acupuncture as it is typically 
performed in practice. Point selection 
was based on the general principles of 
acupuncture and Traditional Chinese 
Medicine (ref). The treatment was 
modiﬁ   ed over the course of the 
study to accommodate the individu-
al’s changing pattern of pain, sleep or 
other health issues.29
(B)  The verum points consisted of oblig-
atory points and additional points 
individually chosen by the physi-
cians on the basis of traditional 
Chinese medicine diagnosis for syn-
dromes (including tongue diagnosis), 
acupuncture channels related to the 
individual headache area and ah shi 
points (locus dolendi points).30
(C) The acupuncture protocol was based 
on the concept of adequacy of treat-
ment, (ref) survey results, (ref) a consen-
sus workshop and recommenda  tions 
from traditional Chinese protocols. 
We did not allow moxibustion, cup-
ping, herbs or electroacupuncture. For 
each individualised treatment session 
between 6 and 10 acupuncture points 
from 16 commonly used local and dis-
tal points were selected. Local points 
were SP9, SP10, ST34, ST35, ST36, 
Xiyan, GB34 and trigger points. Distal 
points were LI4, TH5, SP6, Liv3, ST44, 
KI3, BI60 and GB41.31
STRICTA ITEM 2: DETAILS OF NEEDLING
Item 2a: Number of needle insertions 
per subject per session (mean and range 
where relevant)
Explanation
It is recommended that the reporting of this 
item should include a total of needle inser-
tions per subject per session. This item is 
relevant to all designs of randomised con-
trolled trials, from pragmatic to explana-
tory. For more explanatory designs where 
a formula of points is prescribed, the num-
ber of needle insertions should be reported 
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Table 2  Checklist of CONSORT items and the non-pharmacological trials extension to CONSORT (with STandards for Reporting Interventions in 
Clinical Trials of Acupuncture (STRICTA) extending CONSORT item 5 for acupuncture trials)
Section/topic
Item 
number CONSORT 2010 statement* – checklist item10
Additional items from the 
non-pharmacological trials 
extension to CONSORT14
Describe Add
Title and abstract   1a Identiﬁ  cation as a randomised trial in the title In the abstract, description of the experimen-
tal treatment, comparator, care providers, 
centres and blinding status
  1b Structured summary of trial design, methods, results and conclusions; for 
speciﬁ  c guidance, see CONSORT for abstracts58 59
Introduction
  Background and objectives   2a Scientiﬁ  c background and explanation of rationale –
  2b Speciﬁ  c objectives or hypotheses
Methods
  Trial design   3a Description of trial design (eg, parallel, factorial) including allocation ratio
  3b Important changes to methods after trial commencement (eg, eligibility 
criteria), with reasons
  Participants   4a Eligibility criteria for participants When applicable, eligibility criteria for cen-
tres and those performing the interventions   4b Settings and locations where the data were collected
  Interventions   5 The interventions for each group with sufﬁ  cient details to allow replica-
tion, including how and when they were actually administered
Precise details of both the experimental 
treatment and comparator—see table 1 
above for details
  Outcomes   6a Completely deﬁ  ned prespeciﬁ  ed primary and secondary outcome mea-
sures, including how and when they were assessed
–
  6b Any changes to trial outcomes after the trial started with reasons
  Sample size   7a How sample size was determined When applicable, details of whether and how 
the clustering by care providers or centres 
was addressed
  7b When applicable, explanation of any interim analyses and stopping 
guidelines
 Randomisation
  Sequence  generation   8a
 8b
Method used to generate the random allocation sequence
Type of randomisation; details of any restriction (eg, blocking and block size)
When applicable, how care providers were 
allocated to each trial group
    Allocation concealment   9 Mechanism used to implement the random allocation sequence (eg, 
sequentially numbered containers), describing any steps taken to conceal 
the sequence until interventions were assigned
 –
    Implementation 10 Who generated the random allocation sequence, who enrolled partici-
pants, and who assigned participants to interventions
–
  Blinding 11a If done, who was blinded after assignment to interventions (eg, partici-
pants, care providers, those assessing outcomes) and how
Whether or not those administering co-inter-
ventions were blinded to group assignment
11b If relevant, description of the similarity of interventions If blinded, method of blinding and description 
of the similarity of interventions
  Statistical methods 12a Statistical methods used to compare groups for primary and secondary 
outcomes
When applicable, details of whether and how 
the clustering by care providers or centres 
was addressed
12b Methods for additional analyses, such as subgroup analyses and adjusted 
analyses
Results
Participant ﬂ  ow (a diagram is strongly 
recommended)
13a For each group, the numbers of participants who were randomly 
assigned, received intended treatment and were analysed for the primary 
outcome
The number of care providers or centres 
performing the intervention in each group 
and the number of patients treated by each 
care provider or in each centre
13b For each group, losses and exclusions after randomisation, together with 
reasons
  Implementation of intervention – – Details of the experimental treatment and 
comparator as they were implemented
  Recruitment 14a Dates deﬁ  ning the periods of recruitment and follow-up –
14b Why the trial ended or was stopped
  Baseline data 15 A table showing baseline demographic and clinical characteristics for 
each group
When applicable, a description of care provid-
ers (case volume, qualiﬁ  cation, expertise, etc) 
and centres (volume) in each group
Continued
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Table 2 Continued
Section/topic
Item 
number CONSORT 2010 statement* – checklist item10
Additional items from the 
non-pharmacological trials 
extension to CONSORT14
Describe Add
  Numbers analysed 16 For each group, number of participants (denominator) included in each 
analysis and whether the analysis was by original assigned groups
–
  Outcomes and estimation 17a For each primary and secondary outcome, results for each group and the 
estimated effect size and its precision (eg, 95% CI)
–
17b For binary outcomes, presentation of both absolute and relative effect 
sizes is recommended
  Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses 
and adjusted analyses, distinguishing prespeciﬁ  ed from exploratory
–
  Harms 19 All important harms or unintended effects in each group; for speciﬁ  c guid-
ance see CONSORT for Harms60
–
Discussion
  Limitations 20 Trial limitations, addressing sources of potential bias, imprecision and, if 
relevant, multiplicity of analyses
  Generalisability 21 Generalisability (external validity, applicability) of the trial ﬁ  ndings Generalisability (external validity) of the 
trial ﬁ  ndings according to the intervention, 
comparators, patients and care providers 
and centres involved in the trial
  Interpretation 22 Interpretation consistent with results, balancing beneﬁ  ts and harms, and 
considering other relevant evidence
In addition, take into account the choice of 
the comparator, lack of or partial blind-
ing, unequal expertise of care providers or 
centres in each group
Other information
  Registration 23 Registration number and name of trial registry
  Protocol 24 Where the full trial protocol can be accessed, if available
  Funding 25 Sources of funding and other support (eg, supply of drugs); role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 explanation and elaboration11 for important clariﬁ  cations on all the items. If relevant, 
we also recommend reading CONSORT extensions for cluster randomised trials,61 non-inferiority and equivalence trials,62 herbal interventions,63 and pragmatic trials.16 Moreover, 
additional extensions are forthcoming. See http://www.consort-statement.org (accessed April 2010), for those and also for up-to-date references relevant to this checklist.
as a simple total. For more pragmatic 
designs, with individualised treatments, 
the mean and range should be reported. 
Clearly, full details of individualised treat-
ment cannot be reported in every section 
of item 2 below. However, each item 
should be considered and as much infor-
mation given as possible.
Examples
(A) The protocol allowed for up to 10 
treatments per patient, the precise 
number being agreed between patient 
and practitioner. A total of 1269 treat-
ments were provided, an average 
of 8.6 treatments per patient (range 
1–10) and 9.6 needles per treatment 
(range 6–12). See (table) for variations 
between practitioners.32
(B)  Disposable stainless steel needles 
(0.2×50 mm, Seirin) were inserted 
into the skin over the trigger point 
to a depth of 10–30 mm, appropriate 
to the muscle targeted, attempting to 
elicit a local muscle response using the 
‘sparrow pecking’ technique. After the 
local twitch response was elicited or a 
reasonable attempt made, the needle 
was retained for a further 10 min. The 
mean number of insertions was 3.3.33
(C) In the real acupuncture group, the 
acupuncture points Hegu (LI4), Jiache 
(ST6), Xiaguan (ST7) and Yifeng (SJ17) 
were used unilaterally on the tooth 
extraction side.34
Item 2b: Names (or location if no standard 
name) of points used (uni-/bilateral)
Explanation
The point descriptions in the seminal 
classic texts, such as the Huangdi Neijing 
(Inner Canon of the Yellow Emperor) are 
rare and vague. The depiction of acupunc-
ture points in relation to precise anatom-
ical structures dates back only 100 years. 
Since the   mid-1950s a process of stan-
dardisation has been taking place, and 
the acupuncture point descriptions based 
on anatomical locations and proportional 
cun measurement systems have served 
as a blueprint for many Western transla-
tions. It should be noted that these loca-
tions have not been universally adopted. 
Given this historical context, it remains 
  important to know which acupuncture 
points have been used in clinical trials, 
with as accurate descriptions as possible 
of the location of these points, and, where 
relevant, the method used to identify the 
points.
The speciﬁ   c point locations used in 
treatments where standardised should be 
described by an accepted nomenclature 
(eg, GB21)35 or by an anatomical location 
where there is no accepted name. Whether 
the needles are inserted unilaterally or 
bilaterally should be stated. For protocols 
with partially individualised prescriptions, 
list any prescribed essential or optional 
points, and describe (in the Results sec-
tion) both the points used at every visit, 
and all the points used on an ad hoc basis. 
If the list is extensive, the most commonly 
used points (with percentages) should be 
reported. Where protocols specify using 
fully individualised point prescriptions, 
authors should consider the best way 
to report the points used—for example, 
by listing all points across all subjects or 
by identifying the most commonly used 
points if the list is extensive.
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Examples
(A)  We based the acupuncture point 
selections on TCM meridian theory 
to treat knee joint pain, known as 
the ‘Bi’ syndrome. These points con-
sisted of ﬁ  ve local points (Yanglinquan 
(Gall bladder meridian point 34), 
Yinlinquan (Spleen meridian point 9), 
Zhusanli (Stomach meridian point 
36),  Dubi (Stomach meridian point 
35) and extra point Xiyan) and four 
distal points (Kunlun (Urinary blad-
der, meridian point 60), Xuanzhong 
(Gall bladder meridian point 39), 
Sanyinjiao (Spleen meridian point 6) 
and Taixi (Kidney meridian point 3)) 
on meridians that traverse the area 
of pain (refs). The same points were 
treated for each affected leg. If both 
knees were affected, nine needles 
were inserted in each leg.21
(B) The verum acupuncture (VA) group 
received acupuncture with a 0.25×40 
mm stainless steel needle (Asia-Med, 
Munich, Germany) at LI4, which is 
situated between the ﬁ  rst two meta-
carpal bones on the dorsal side of both 
hands at the top of the muscle belly 
(ﬁ  gure provided).36
(C)  The most frequently treated local 
points were BL23, BL25, GB30, DU4, 
BL26 and the extra point Huatuojiaji 
(table provided)…. The most fre-
quently treated distant points were 
BL40, KId3, GB34, BL60, SI3 and 
DU20. In most cases, 8–12 local points 
and 4–6 distant points were used. 
Physicians used additional acupunc-
ture points in 565 of the treatment 
sessions. The most frequently used 
additional local points were LI4, ST40, 
BL17, SP6 and ST36.27
Item 2c: Depth of insertion, based on a 
speciﬁ  ed unit of measurement or on a 
particular tissue level
Explanation
The depth of insertion should be expressed 
using the Chinese measurement of the cun; 
as anatomical depth—for example, of sub-
cutaneous tissue, fascia, muscle or perios-
teum; or in millimetres. For some trials, 
the protocol might specify the angle and 
direction of insertion together with depth 
of insertion, in which case these should 
also be reported.
Examples
(A)  All needle placements were performed 
by an experienced acupuncturist at a 
premarked depth of 4 mm from the 
tip of the needle.37
(B)  The depth of needle insertion varied 
with thickness of the skin and sub-
cutaneous fatty tissues at the site of 
the acupuncture points; it was usually 
1–1.5 cm.38
(C)  Shallow and light needling stimu-
lation (1–2 mm) using ﬁ  ne  needles 
(0.18–0.16 mm) inserted with the aid 
of insertion tubes was emphasised. 
Points were needled at a 10–20° angle 
with a two-hand needling technique, 
generally in the direction of the ﬂ  ow 
of the channel.39
Item 2d: Response sought (eg, de qi or 
muscle twitch response)
Explanation
If the study protocol requires that spe-
ciﬁ  c responses to needling be elicited—for 
example, the de qi sensation in traditional 
Chinese acupuncture, the muscle twitch 
in trigger point treatment or muscle con-
traction in electroacupuncture, these elic-
ited responses should be reported. Where 
relevant, the authors should differenti-
ate between the responses required in 
the protocol and those actually obtained 
(which should be reported in the Results 
section).
Examples
(A)  The trigger point group received treat-
ment at trigger points. The correct 
application of the technique requires 
experience in palpation and localisa-
tion of taut muscle bands and myofas-
cial trigger points. Precise needling of 
myofascial trigger points provokes a 
brief contraction of the muscle ﬁ  bres. 
This local twitch response must be 
elicited for successful therapy but it 
may be painful and post-treatment 
soreness is frequent.33
(B)  In contrast with TCM-style acu-
puncture, we did not employ vigor-
ous manipulation in order to elicit a 
strong de qi sensation (deﬁ  ned as a 
feeling of heaviness around the acu-
puncture point). (ref) Practitioners 
focused instead on feeling the 
response to stimulation as an ‘echo’ 
sensation experienced on the receiv-
ing hand, while the active hand per-
formed the actual needling. Attention 
was placed on reactivity or change in 
diagnostic areas, especially the pulse 
and abdomen. By carefully assessing 
changes in palpatory ﬁ  ndings,  the 
treatment was adjusted continuously 
based on the patient’s response. 
Before needling, the ‘live’ points 
were identiﬁ   ed by palpation—th  at 
is, subtle changes at the skin level, or 
upon touch or pressure, for that par-
ticular patient.39
Item 2e: Needle stimulation (eg, manual, 
electrical)
Explanation
Needle stimulation techniques, where 
used, should be clearly described for all 
points. For manual stimulation, such tech-
niques include lifting, thrusting or rotating 
the needle to manipulate the de qi sensa-
tion. For electrical stimulation, the current, 
amplitude and frequency settings should 
be recorded.
Examples
(A) This mode of (manual) stimulation 
was provided via the acupuncture 
needles, which were placed in the pre-
marked depth at the marked sites. The 
needle was rotated by an experienced 
acupuncturist with the index ﬁ  nger 
and thumb in an alternating clock-
wise and counter-clockwise fashion at 
the rate of three to ﬁ  ve rotations per 
second.37
(B)  Electrical stimulation was given to the 
anterior part of the knee for 10 min 
and then 10 min for the posterior part 
using a battery-operated, four-channel, 
‘AS Super 4’ Electrostimulator (RDG 
Medical, Surrey, UK) which generated 
low-frequency, square-wave (2–10 
Hz) pulses of 1 ms duration for 10 
min. (ref) In both groups, the appa-
ratus was attached to needles at the 
two Xiyan points, SP9 and GB34, and 
BL40 and BL57. Electrical stimulation 
was delivered at 6 Hz at a constant 
current. Voltage was set at a level just 
above the pain threshold.38
Item 2f: Needle retention time
Explanation
Needle retention times should be reported 
as either a standard or a mean and range. 
Authors should make it clear that they are 
reporting the time elapsed between the 
insertion and removal of needles (reten-
tion time) and distinguish it from treat-
ment time, which may include other pro-
cedures such as history taking, discussion 
and preparation for treatment.
Examples
(A) Each participant was treated bilater-
ally and had a total of six needles 
inserted for the duration of the 
treatment. A draining technique 
was used and the needles were left 
for a period of 30 min. The prac-
titioner returned to check on the 
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  participant at regular intervals dur-
ing the intervention.40
(B)  Needles were withdrawn immediately 
for toniﬁ  cation and retained for up to 
20 min for the evens technique.23
(C)  Therapists allow 25 (minimum) to 
35 (maximum) minutes between 
insertion of the last needle and ces-
sation of treatment and during that 
time they are to revisit the needles as 
appropriate.41
(D) The patients in group A were dry nee-
dled for a few seconds. For trigger 
point inactivation by dry needling … 
it is especially important not to apply 
too strong a stimulus because this 
may produce a ﬂ  are-up of the patient’s 
symptoms.42
Item 2g: Needle type (diameter, length and 
manufacturer or material)
Explanation
Details should be given of the types of nee-
dles used, including the diameter and length 
as well as the manufacturer and/or the 
material. This information is of importance 
since the effect of different metals or needle 
sizes on the body is not known. For trials 
using a variety of different types of needles, 
the ranges of diameters and lengths as well 
as types of material should be reported.
Examples
(A)  Seirin 36-gauge 2.5 inches long unused 
sterile L-type needles were used for 
the study.37
(B)  The verum acupuncture group received 
acupuncture with a 0.25×40 mm stain-
less steel needle (Asia-Med) at LI4.36
STRICTA ITEM 3: TREATMENT REGIMEN
Item 3a: Number of treatment sessions
Explanation
The planned number of sessions and fre-
quency of treatment should be clearly 
documented. The actual number of treat-
ments received by participants should be 
reported in the Results section. If there is 
variation between patients, then the mean 
and range should be reported.
Examples
(A) The true acupuncture (experimental) 
group underwent 26 weeks of gradually 
tapering treatment according to the fol-
lowing schedule: 8 weeks of two treat-
ments per week followed by 2 weeks 
of one treatment per week, 4 weeks of 
one treatment every other week and 12 
weeks of one treatment per month.21
(B)  In all groups, participants were asked 
to attend treatment sessions twice 
weekly for 12 weeks (24 treatments). 
We considered participants who 
attended 80% or more (≥19 of 24) of 
acupuncture sessions to have com-
pleted a full course of treatment.43
Item 3b: Frequency and duration of 
treatment sessions
Explanation
The frequency and duration of sessions 
should be documented, with mean and 
range to be reported where there is var-
iation across patients. Any variation in 
frequency of treatment (eg, if subjects are 
to be treated twice weekly in the ﬁ  rst 2 
weeks then once a week for the next 6 
weeks) should be clearly reported.
Example
(A)  Acupuncture was administered a 
maximum of eight times, twice dur-
ing each of the ﬁ  rst 3 weeks and once 
during each of the following 2 weeks, 
for 30 min at each session. One month 
after this series of treatments had been 
completed and evaluated, the patients 
were offered a maximum of two fol-
low-up treatments of the same kind, 
1 week apart.44
STRICTA ITEM 4: OTHER COMPONENTS 
OF TREATMENT
Item 4a: Details of other interventions 
administered to the acupuncture group 
(eg, moxibustion, cupping, herbs, 
exercises, lifestyle advice)
Explanation
Additional components of treatment refer 
to the auxiliary techniques, prescribed 
self-treatment and lifestyle advice pro-
vided by the practitioner. All additional 
components, whether carried out by the 
practitioner or patient and whether inte-
gral or adjunctive to the acupuncture 
needling, should be described clearly. For 
acupuncture-related interventions, such as 
moxibustion or cupping, detail should be 
provided equivalent to that recommended 
for acupuncture needling. If the protocol 
speciﬁ   es the options of prescribed self-
help treatments such as Qigong or muscle 
stretching exercises and/or lifestyle advice 
such as dietary changes based on acupunc-
ture-related diagnostic criteria, then these 
too must be reported. The frequency with 
which the advice was given, and par-
ticipants’ compliance with this advice, 
should be reported. ‘Other components of 
treatment’ should be distinguished from 
‘co-interventions’—that is, interventions 
that are provided additionally to both 
groups, which should be fully reported as 
described in STRICTA item (6b) below.
Examples
(A) In addition to needling, moxibustion 
or thermal stimulation of the acu-
points was used forming very ﬁ  ne 
wool of mugwort (Artemisa vulgaris) 
into minute, thread-size punks (Okyū) 
and placing them on a thin layer of a 
herbal cream (Shiunko). The moxa was 
lit with an incense stick and the pro-
cess was repeated several times until 
warmth was felt by the patient.39
(B) Following application of the studs, 
patients were instructed to apply 
pressure to the stud by making small 
circular movements with the ﬁ  ngers 
of the opposite hand, 2–3 cycles/s for 
1–2 min/point. As is typical for self-ad-
ministered acupressure, patients were 
encouraged to apply acupressure this 
way on waking, in the early afternoon 
and during any exacerbation of symp-
toms. Initial instruction was provided 
verbally, at which time patients were 
asked to conﬁ   rm their understand-
ing by demonstrating the procedure. 
Patients also were given easy-to-read 
written materials describing the acu-
pressure procedure.45
(C) Chinese herbal medicine was to be 
taken three times per day over a period 
of 6 weeks and parallel to acupuncture 
treatment … All herbs used in the pre-
sent study were imported from China 
by a single TCM herbal medicine 
import company (Sinores, Lueneburg, 
Germany) … All herbs were prepared 
in dried, minced pieces and then sealed 
in generic paper sachets by a pharma-
cist in order to render the herbal for-
mulation non-identiﬁ  able for patients 
… In addition to the basic formula, 
every patient received a second addi-
tional formula tailored to his or her 
individual TCM diagnosis.46
Item 4b: Setting and context of treatment, 
including instructions to practitioners, and 
information and explanations to patients
Explanation
The setting and context of treatment can 
also provide important additional com-
ponents to treatment.47 Context includes 
instructions to practitioners that might 
modify their normal practice—for exam-
ple, prescribing or proscribing explana-
tions to patients about their diagnosis. 
For patients, the context includes the 
information they have been given about 
the trial that might be expected to mod-
ify outcomes. Therefore, the informa-
tion that the patient receives regarding 
the treatment and control intervention 
should be reported, including any relevant 
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wording on consent forms and informa-
tion leaﬂ  ets designed to inﬂ  uence beliefs 
or expectations. For example, describing 
a sham acupuncture control as ‘a type of 
acupuncture’ may have a different effect 
on outcome than saying it is ‘not acupunc-
ture, but will involve a similar experience 
to acupuncture’.
Examples
(A) The ﬁ  rst acupuncturist was the ‘diag-
nosing acupuncturist’ (DA), whom 
the patient saw for the initial consul-
tation, and before and after each treat-
ment. A full case history was taken 
by the DA, together with tongue 
and pulse examination, to arrive at 
an individual diagnosis in accordance 
with the principles of TCM, with an 
additional lesser emphasis on Five 
Element Acupuncture (refs). Although 
all patients in the study had irritable 
bowel syndrome, this corresponded to 
a wide range of TCM patterns, making 
individual diagnosis essential. Dietary 
and lifestyle advice (important in treat-
ment according to TCM principles) 
was given to all patients by the DA, 
who then selected acupuncture points. 
The second ‘treating acupuncturist’ 
(TA) opened the randomisation enve-
lope, and for the duration of the study 
remained the only individual aware of 
treatment allocation. The TA carried 
out the treatment— either according 
to instructions issued by the DA or 
using sham points, depending on the 
randomisation.48
(B)  Patients were informed about acupunc-
ture and minimal acupuncture in the 
study as follows: ‘in this study, different 
types of acupuncture will be compared. 
One type is similar to the acupuncture 
treatment used in China. The other 
type does not follow these principles, 
but has also been associated with posi-
tive outcomes in clinical studies’.27
STRICTA ITEM 5: PRACTITIONER 
BACKGROUND
Item 5: Description of participating 
acupuncturists (qualiﬁ  cation or professional 
afﬁ  liation, years in acupuncture practice, 
other relevant experience)
Explanation
Characteristics of the acupuncturists pro-
viding treatment should be reported, 
including qualiﬁ  cation or afﬁ  liation, years 
in acupuncture practice, as well as any 
other experience that may be relevant to 
the trial. Relevant differences (if any) in 
the qualiﬁ  cation, training and experience 
of the participating acupuncturists should 
be highlighted. The recent survey of 
authors of acupuncture trials and reviews 
reinforced the need for these characteris-
tics to be reported well,12 especially since 
the actual level of reporting has histori-
cally been poor.13 In trials where different 
acupuncturists provide treatment to dif-
ferent treatment arms, the background of 
both groups should be reported. The eli-
gibility criteria for acupuncturists should 
be explained, as these will inﬂ  uence gen-
eralisability of the trial results. Where 
there are known to be potential variations 
between practitioners, selecting a random 
sample of practitioners will reduce exper-
tise bias and help improve the applicabil-
ity of the results.49
Examples
(A)  Physicians had a median of 350 h (range 
140–2508 h) of acupuncture training 
before participating in the trial; 33 
(73%) had the B-diploma. Seventeen 
(17; 38%) trial physicians taught acu-
puncture in accredited postgraduate 
courses. The physicians had used acu-
puncture in their practices for an aver-
age of 11 years (median 10, range 0–25) 
and had treated 346 patients (range 
22–1200) with acupuncture in the year 
before the trial. Forty-one physicians 
(92%) indicated that they frequently 
or always make a Chinese syndrome 
diagnosis before starting treatment.27
(B) Eight US-trained and licensed acu-
puncturists with a median of 10 years 
of experience (range 4–18 years) pro-
vided study treatments in their pri-
vate ofﬁ  ces. One investigator trained 
the acupuncturists in the study proce-
dures to increase their comfort with 
delivering all four treatments and 
monitored compliance with the pro-
tocol throughout the study.43
(C) Of the 11 midwives participating in the 
study, six had been taught acupuncture 
for mid-wives at the Norwegian School 
of Acupuncture/NFKA. These six gave 
real and false acupuncture, whereas 
the others, who had been trained in 
acupuncture by the six, were allowed 
only to give false acupuncture.50
STRICTA ITEM 6: CONTROL OR 
COMPARATOR INTERVENTIONS
Item 6a: Rationale for the control or 
comparator in the context of the research 
question, with sources that justify the 
choice(s)
Explanation
The rationale for choice of control or 
comparator should be presented and 
justiﬁ  ed in relation to the research ques-
tion and the methodology. In studies in 
which a group receiving acupuncture is 
compared with another group, the con-
trol or comparator can be sham acupunc-
ture, usual care, an active treatment, a 
waiting list or no treatment. Whereas 
‘control’ is sometimes used for a group 
that receives no intervention, the term 
‘comparator’ may be more appropri-
ate for an active intervention, such as 
physiotherapy, for which the intended 
action of the comparator is expected to 
be therapeutic. If using an acupuncture-
like control in a participant-blinded trial 
then one of the following terms: active 
acupuncture control, penetrating needle 
control or non-penetrating sham needling 
control might be helpful descriptors. 
Control procedures involving invasive or 
non-invasive sham needling techniques 
may be therapeutically active, evok-
ing neurophysiological and/or   localised 
immune and circulatory responses. The 
extent to which sham acupuncture nee-
dling, whether penetrating or not, might 
elicit acupuncture-speciﬁ  c  physiological 
mechanisms is not known, and is in part 
a consequence of our lack of knowledge 
of the mechanism(s) of true acupuncture. 
There are also variations in assump-
tions about the precision required for 
point location, as for some clinicians 
and investigators acupuncture points are 
considered as areas of reactivity rather 
than points of action. Such assumptions 
have a bearing on the integrity of the 
sham as an appropriate control. Some 
non-needling control procedures can be 
assumed to be physiologically inert, such 
as an inactivated transcutaneous electri-
cal nerve stimulation machine; however, 
these procedures may not have the same 
total psychophysiological credibility as 
acupuncture, thereby compromising the 
interpretation of the results. Sources that 
led to the choice of control, such as lit-
erature or expert opinion, should also 
be reported and referenced. The author 
should reference prior work that sup-
ports the use of the selected comparator, 
such as from the conclusion of a system-
atic review or from another randomised 
controlled trial.
Examples
(A) ‘Sham’ acupuncture points were cho-
sen from three different areas on the 
body (the anterior thigh distally, the 
posterior thigh and the lateral aspect 
of the lower back), which do not cor-
respond to recognised acupuncture 
points and are deemed to have no 
therapeutic value.48
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(B) International guidelines suggest that 
the best package of care for this patient 
group is one that includes patient edu-
cation, advice and exercise (ref) …. 
Randomised clinical trials consistently 
show the beneﬁ  t of exercise for knee 
pain in older adults (refs). Recent stud-
ies also highlight the need to provide 
adequate instruction, feedback and 
practice in order to ensure that the key 
muscle groups around the knee, such as 
the quadriceps, are activated (ref). The 
European League Against Rheumatism 
recommendations have recently been 
updated and in particular, advocate 
exercise for knee pain related to osteo-
arthritis (ref). In line with this evidence 
base, the current trial was designed so 
that all participants receive a package of 
care which includes education, advice 
and exercise.41
(C) For this study a special ‘placebo nee-
dle’ was designed by Streitberger. 
The needle body is not ﬁ  xed inside 
the copper handle. Its tip is blunt 
and when it touches the skin, a 
small pricking sensation is felt by the 
patient, simulating the puncture of the 
skin. The handle of the needle moves 
over the needle, the needle is short-
ened. Patients ‘see’ the needle moving 
inside their body … This needle was 
tested in 60 volunteers and proved to 
be sufﬁ  ciently credible to be used in 
our clinical trial as a control (ref).51
Item 6b: Precise description of the control 
or comparator. If sham acupuncture or 
any other type of acupuncture-like control 
is used, provide details as for items 1–3 
above
Explanation
A precise description of the components 
of the control or comparator should be 
presented. If the control treatment is an 
acupuncture-like intervention, such as a 
form of sham acupuncture, then it should 
be speciﬁ   ed whether the sham is inva-
sive (penetrating the skin) or non-invasive 
(non-penetrating). The theoretical basis, 
needling details and regimen of an acu-
puncture-like control need to be reported 
in the same way as is set out in STRICTA 
items 1–3 above. The lack of a worldwide 
consensus on the location and size of acu-
puncture points reinforces the importance 
of accurate documentation of the sham 
points actually used, their precise location 
and the method used to locate them. If 
usual care or another active treatment is 
the comparator, all the components should 
be reported in full detail. This will enable 
readers to compare usual care as provided 
in the trial with what is usually provided 
to participants in another setting. Where 
usual care is also provided to those receiv-
ing acupuncture, these data will also allow 
readers to compare the intensity of usual 
care in the comparator arm with that of 
the experimental arm. If it is a waiting list 
arm, then the period of waiting needs to 
be speciﬁ  ed. While precise description of 
the control or comparator is fairly straight-
forward in principle, the more complex 
the components, the more care is required 
to specify them precisely.
Examples
(A) Acupuncturists inserted two needles 
into the sham points in the abdominal 
area, approximately 3 cm lateral to and 
slightly above the umbilicus bilater-
ally and then immediately applied two 
pieces of adhesive tape next to the nee-
dles. In addition, they tapped a mock 
plastic needle guiding tube on the sur-
face of each of the nine true points in 
the leg to produce some discernible 
sensation and then immediately 
applied a needle with a piece of adhe-
sive tape to the dermal surface, with-
out needle insertion, of each point for 
a total of 20 min. The sham acupunc-
ture procedure was given on the same 
schedule as the experimental group 
and used the same active needle place-
ments, except actual insertion did not 
occur at these nine points. Although 
electrical stimulation did not occur, a 
mock transelectrical stimulation unit 
(which emitted a sound and possessed 
a blinking light) was attached to the 
sham needles at the knee. To facilitate 
blinding, we used screens in both treat-
ment and sham groups which were 
placed below the abdomen to prevent 
participants from actually observing 
the true or sham procedures at the 
knee area but to allow them to observe 
the procedure being performed in the 
abdomen area.21
(B)  In each session, at least ﬁ  ve out of 10 
predeﬁ   ned distant non-acupuncture 
points (ref) were needled bilaterally 
(at least 10 needles) and superﬁ  cially 
using ﬁ   ne needles (ie, minimal acu-
puncture). ‘De qi’ and manual stimula-
tion of the needles were avoided. All 
acupuncturists received oral instruc-
tions, a videotape and a brochure 
with detailed information on sham 
acupuncture.52
(C) Conservative therapy involved 10 vis-
its to practitioners with consultation 
and a prescription for diclofenac, up 
to 150 mg/day, or rofecoxib, 25 mg/
day, as needed, until week 23.53
(D) Patients received the same treatment 
as in the standard group but in addi-
tion did stabilising exercises modi-
ﬁ  ed because of the pregnancy. (refs) 
The training programme started by 
emphasising activation and control 
of local deep lumbopelvic muscles. 
Training of more superﬁ  cial muscles in 
dynamic exercises to improve mobil-
ity, strength and endurance capac-
ity was gradually included. Patients 
received treatments individually for 
a total of 6 h during 6 weeks. They 
were told to integrate the exercises in 
daily activities and to exercise in short 
sessions on several occasions during 
the day.54
DISCUSSION
This revised STRICTA statement has been 
designed to help improve the reporting of 
interventions in clinical trials of acupunc-
ture, with the intention that it will help 
authors of acupuncture trials provide read-
ers with a clear, accurate and transparent 
account of their acupuncture protocols 
as well as their control and/or compara-
tor procedures. In addition to revising the 
STRICTA checklist, we have improved the 
explanations of each item and provided 
examples of good reporting. To enhance 
awareness, endorsement and adherence, 
the revised STRICTA statement has been 
developed as an extension to CONSORT. 
Authors of clinical trials of acupuncture 
should use the STRICTA recommenda-
tions for the acupuncture intervention 
(item 5 in the CONSORT 2010 statement) 
in conjunction with the other 25 items of 
the checklist in the main CONSORT guide-
lines.10 11 The extension to CONSORT for 
non-pharmacological interventions is also 
highly relevant to acupuncture trials.14 15 
There are other extensions to CONSORT 
that may be relevant, depending on the 
type of trial design, including extensions 
for cluster trials, equivalence and non-
inferiority trials and pragmatic trials, and 
the reporting of abstracts and of harms 
(eg, adverse events) associated with the 
intervention. The most recent versions of 
all CONSORT guidance documents can be 
found on the CONSORT website (http://
www.consort-statement.org, accessed 16 
April 2010).
A complete, accurate and transpar-
ent trial report facilitates dissemination, 
interpretation, translation and replica-
bility. There continues to be a need for 
better reporting generally, as has been 
highlighted in a recent study of what is 
missing from descriptions of treatments 
in trials and reviews.55 The authors found 
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that elements of the intervention were 
missing in half of the published articles 
that they reviewed, giving insufﬁ  cient 
detail—for example, with practitioners 
unable to use the treatments as described 
and researchers unable to replicate stud-
ies. This ﬁ  nding is similar to that from a 
review of authors of acupuncture trials.12 
Improved reporting reduces reader ambi-
guity in interpretation, is likely to increase 
credibility and application of the results 
by providing better evidence on which to 
base decisions on patient care.
Reporting guidelines do help to improve 
the quality of reporting randomised trials,56 
although it is difﬁ   cult to observe their 
maximal beneﬁ  t because too few journals 
endorse reporting guidelines57 and fewer 
adhere to them.57 To maximise this poten-
tial, we encourage journals to unambigu-
ously endorse the revised STRICTA report-
ing guidelines. This can be most readily 
achieved by updating journal Instructions 
to Authors, thereby alerting prospective 
authors. In addition, we encourage jour-
nals to implement strategies to improve 
author adherence to reporting guidelines. 
These efforts might also help peer review-
ers and journal editors in deliberating the 
merits of such trials.
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